Fifth Eye, Inc.

Fifth Eye, Inc. specializes in clinical management support software, specifically tools designed to analyze hemodynamic instability and apnea-hypopnea index (AHI) data. These devices assist clinicians in monitoring and assessing patient respiratory and circulatory conditions within clinical settings.

Fifth Eye, Inc. is based in the United States, which means its devices fall under FDA regulation. Since the company’s products are classified as Class II devices, they require compliance with FDA pathways like 510(k) premarket notifications and the Unique Device Identifier (UDI) system to ensure safety and effectiveness.

Fifth Eye, Inc.’s devices are listed in the FDA’s 510(k) and UDI databases because these are the primary pathways for Class II medical devices in the U.S. The 510(k) process ensures that new devices meet safety and performance standards compared to existing ones, while the UDI system provides a standardized way to track and trace devices throughout their lifecycle.

Fifth Eye, Inc.’s devices are classified as Class II, meaning they pose moderate risk and require special controls beyond general controls to ensure safety and effectiveness. This classification means they must comply with FDA-mandated regulations, including 510(k) submissions and UDI labeling, to demonstrate their performance and reduce risks to patients.